• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • TBK1 Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • Adenosine Kinase Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Could an Inhibitor of Phosphodiesterase Activity be a Treatment for Alzheimer’s?

by Bellbrook Labs / Tuesday, 14 May 2019 / Published in Emerging Targets, HTS Assays

As we continue to increase our lifespan, diseases such as Alzheimer’s will subsequently persist to develop. With up to 4.5 million Americans currently affected, there’s a strong desire to find a cure or at the very least some relief from the symptoms.¹   Neurodegeneration derived memory loss is the most common and perhaps the most devastating result of the disease. It’s not just forgetting a name or face, but losing the ability to do routine tasks such as shower and make breakfast.

Although there is a genetic component found in Alzheimer’s Disease (AD) there are hallmark features that people associate with the disease such as amyloid plaques, neurofibrillary tangles, and neuronal loss. The toxic clustering of proteins and neuron damage has a consequent harmful effect on nerve cell synaptic connections.

Can PDE Inhibition Unlock A Treatment?

When finding ways to eliminate memory loss in Alzheimer patients, many researchers focus on synaptic strengthening where a second messenger (cyclic adenosine monophosphate (cAMP)) cascade regulates gene transcription.

Of particular interest is a specific type of synaptic strengthening, long-term potentiation (LTP) which is involved in memory and learning. In this process, a protein known as cAMP-responsive element-binding protein (CREB) gets phosphorylated in order to activate transcription in memory-related genes.² cAMP triggers the phosphorylation. To regulate this signaling pathway, a special enzyme, cyclic nucleotide phosphodiesterase (PDE) catalyzes the degradation of cAMP. Obviously, this pathway is ripe for causing memory associated issues if not in optimal working condition.

As PDEs are key elements within the cAMP cascade, it’s no surprise that many neurodegenerative diseases including Alzheimer’s are associated with anomalies found in these cyclic nucleotide enzymes. Recent studies have found that inhibiting PDE activity has therapeutic potential for patients with (AD).³

Inhibitor of Phosphodiesterase Activity Shows Potential

An exciting study by Bartolome et al identified S14, a small heterocyclic molecule, as an inhibitor of phosphodiesterase activity. Specifically, S14 is able to inhibit the cAMP-specific PDE7; restoring visual short-term memory.³   In addition to upregulating neurogenesis, the administration of the PDE7 inhibitor increased cAMP and CREB levels in the hippocampus.³   These findings suggest S14 is a promising therapeutic for fighting memory loss for those suffering from AD.

A PDE Activity Assay for Drug Discovery

The following data set provides an example of using the Transcreener AMP²/GMP² Phosphodiesterase Assay with PDE7A to determine inhibitor potency. In the first graph, the enzyme is titrated in the presence and absence of cAMP.

An example dose-response with two known PDE7 inhibitors demonstrates the assay’s ability to measure compound potency. Using the assay to perform a high throughput screen can yield a variety of potential inhibitor chemotypes that can be further developed using SAR to improve drugability. New, more potent, and selective inhibitors for PDE7 could potentially provide treatment options to AD.

References

  1. Conditions G. Genetics Home Reference Alzheimer disease. :1-8. https://ghr.nlm.nih.gov/condition/alzheimer-disease
  2. Teich AF, Nicholls RE, Puzzo D. Synaptic Therapy in Alzheimer ’ s Disease: A CREB-centric Approach. 2015:29-41. https://link.springer.com/article/10.1007/s13311-014-0327-5
  3. Bartolome F, Cueva M De, Pascual C, et al. Amyloid β -induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. 2018:1-15. https://alzres.biomedcentral.com/articles/10.1186/s13195-018-0352-4
Tagged under: Phosphodiesterase Assay, Transcreener AMP/GMP Assay

What you can read next

SIRT6: Keeping Tumor Cells in Check
BellBrook Labs Launches HTS Assay Platform for Targeting GPCR Regulatory Proteins
Glycosyltransferase Activity Assay and Lysosomal Storage Disorders
Using a Glycosyltransferase Activity Assay to Study Glycosylation and the Function of GTs

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Scientist Studying ALKPK1

    The Role ALPK1 in Health and Disease

    ALPK1 (Alpha Kinase 1) is an atypical serine/th...
  • DHX36 RNA Helicase Unwinds G4 RNA Structures

    Resolving the Many Roles of DHX36

    While most researchers are familiar with canoni...
  • Researcher Studying MAPK14

    MAPK14 in Context

    MAPK14 (or p38 alpha or SAPK2a) is a proline-di...
  • PRMT5 Role with Macrophages

    PRMT5 is Innately Interesting

    PRMT5 is a type II arginine methyltransferase t...
  • IRE1 Proteins in ER

    The Multifaceted Roles of IRE1 Are Unfolding

    IRE1 (Inositol-Requiring Enzyme 1) is one of th...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2021 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP